Q2 2020 Dynavax Technologies Corp Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the Dynavax Technologies Second Quarter 2020 Conference Call. As a reminder, this conference call is being recorded. (Operator Instructions) I would now like to turn the conference over to Nicole Arndt, Senior Manager, Investor Relations. You may begin.
Thank you, operator. Good afternoon. Welcome to the Dynavax Second Quarter 2020 Financial Results and Corporate Update Conference Call. Joining me on the call today are Ryan Spencer, Chief Executive Officer; Michael Ostrach, Chief Financial Officer; Robert Janssen, Chief Medical Officer and Senior Vice President, Clinical Development; and Donn Casale, Vice President, Commercial.
Before we begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, revenue expectations, potential peak revenue, the completion of post-marketing study and regarding vaccine development potential with CpG 1018. These statements are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |